论文部分内容阅读
熊去氧胆酸疗法对原发性胆汁性肝硬变(PBC)免疫异常的影响,尤其是对反映胆管破坏的抗细胞角蛋白亚类CK_1抗体效价的影响已明确。作者对此进行了探讨,报告如下。对象和方法对象为16例无症状的 PBC患者、11例有症状的PBC患者。熊去氧胆酸每天600mg,在服药前后检查常规肝功能、血清免疫球蛋白、血清总胆汁酸,用气相色谱分析法测定胆汁酸成分,用单克隆抗体夹心抑制酶联免疫吸附分析法检测血中抗CK_1抗体效价,并行动态观察。结果两组患者的血清碱性磷酸酶、γ-GTP、GOT、GPT、血清总胆汁酸与胆酸之比、血清总胆汁酸与鹅去氧胆酸之比、胆酸与
The effect of ursodeoxycholic acid therapy on immune abnormalities in patients with primary biliary cirrhosis (PBC), and in particular on the titer of the anti-cytokeratin subclass CK1 antibody that reflects bile duct destruction, has been established. The author discusses this, the report is as follows. Subjects and methods were 16 asymptomatic PBC patients and 11 symptomatic PBC patients. Ursodeoxycholic acid daily 600mg before and after taking routine liver function tests, serum immunoglobulin, serum total bile acid, gas chromatography analysis of bile acid composition, with a monoclonal antibody sandwich enzyme-linked immunosorbent assay to detect blood Anti-CK_1 antibody titers were observed in parallel. Results Serum alkaline phosphatase, γ-GTP, GOT, GPT, total bile acid and bile acid ratio, total bile acid and chenodeoxycholic acid ratio,